Objective    To evaluate the therapeutic effect of probucol on delaying the progression of diabetic nephropathy (DN).     Methods    One-hundred-and-two type II diabetes patients with albuminuria (microalbuminuria >1.9 mg/dl) were divided in a probucol group (500 mg/d

n

=51) and a control group (

n

=51) based on the routine drug treatment. A follow-up survey was carried out for 6 months

i

n which the blood pressure

blood lipid (TC

TG

LDL-C and HDL-c)

renal function (s-Cr

BUN and cys-c)

urine protein (microalbuminuria and 24 h urine protein)

glycosylated hemoglobin (HbA1c)

hypersensitive C-reactive protein (hs-CRP)

and liver function (AST

ALT and GGT) were detected. Statistical analyses were also conducted.     Results    During the  6-month follow-up

the data of 5 patients of probucol group and 3 patients of control group were lost.  The blood lipid (TC

TG and LDL-c)

cys-c and hs-CRP of the probucol group after treatment were significantly lower than those of the probucol group before treatment and the control group (

P

<

0.05). The increases of s-Cr

BUN

microalbuminuria and 24-h urine protein in the probucol group were significantly lower than those in the control group (

P

<

0.05). Based on the administration of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ARB/ACEI) drugs (

n

=48)

probucol could suppress the increases of cys-c

hs-CRP

microalbuminuria and 24-h urine protein (

P

<

0.05).     Conclusion    Probucol can reduce the urine protein content and improve the renal function of DN patients

thus delaying the progression of DN. Besides

probucol has a synergic effect with ARB/ACEI drugs on the prevention and treatment of DN.